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Infection of a vascular prosthesis or endovascular stent graft is
probably the most serious complication that may occur after
replacement of the aortic root and aortic arch and dramatically
affects the patient’s outcome. Surgical treatment is always
required as long as the patient is operable, but early and
mid-term morbidities remain signiﬁcant even following a tech-
nically successful repair. Complete resection of the infected
foreign material with debridement of the surrounding tissue has
been increasingly accepted as the best option and most prob-
ably gives the better results. Orthotopic reconstruction is the
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best strategy for all thoracic and thoraco-abdominal pathologies
and the use of biomaterial—homografts or self-made vascular
tubes from xenopericardial tissue—is the most accepted tech-
nique in the literature. In some exceptional situations, endovas-
cular stent graft can be performed as bridging to a more
complete treatment if the general condition of the patient has to
be stabilized, but introduction of more foreign material is usually
not a wise decision in a complex aortic graft infection.
The series reported in the present issue of European Journal
of Cardiothoracic Surgery summarizes the experience of the
Hannover Medical School with a limited number of patients
who presented with infected aortic root and ascending and
aortic arch graft prostheses following different procedures, but
all involving at least the proximal aortic arch [1]. The strategy was
uniform in all patients, and surgery was complicated by substan-
tial early mortality (24%) and early and mid-term morbidity: in 1
patient, very early degeneration of the homograft valve occurred
after 16 months only. In this critical context, it is questionable if
re-replacement with another homograft was the best possible
treatment. At least if the patient was not infected at 3rd oper-
ation, a more durable solution might have been discussed.
In cases where the full aortic arch had to be replaced, the
authors proceeded with a proximal to distal repair, starting the
procedure at the aortic root and performing the most distal
anastomosis (which is the most difﬁcult one) at the end. This
might have required a prolonged perfusion to rewarm the
patient and made the anastomosis technically more demanding;
in fact, the authors report some uncontrollable bleeding that
required additional stent coverage of the anastomosis in the
next few days. Introducing prosthetic material (the endovascular
stent graft) in an infectious setting is not optimal.
Personally, we are not sure that a proceeding like this would
have any advantages: the authors claim that this helped to save
an additional suture line that might have had the potential of
bleeding or later degeneration. Performing the distal anasto-
mosis ﬁrst allows a better visualization of the operative site and
has the additional advantage that rewarming can be started
immediately thereafter: this helps to shorten perfusion times
considerably and may have a positive effect on haemostasis.
In addition to graft and/or endovascular graft excision, we
agree that debridement of all inﬂammatory tissues and appropri-
ate drainage of the prosthetic bed are important principles to
prevent persistence of the infection process. In some instances,
vacuum-assisted wound drainage and delayed sternal closure
may be an interesting option to sterilize the operative site.
Recently, we summarized our experience with vascular graft
and endograft infections in the thoracic and thoraco-abdominal
aortic location over the last 5-year period (2006–10) that were
treated with a self-constructed xenopericardial vascular tube
graft [2]. Fifteen patients with graft infection after prior thoracic
or abdominal aortic replacement were treated with complete
removal of the infected alloplastic material, extensive local
debridement and orthotopic vascular reconstruction by one or
more neo-aortic segments constructed with a bovine pericardial
patch. Perioperative mortality was similar to that described in
the present series 27% (n = 4). All deaths were due to multiorgan
failure as sequelae of the underlying infective process. The mean
follow-up is now 36 months and CT scans has shown regular re-
gional ﬁndings at the operative site in all patients. Freedom from
reinfection was 100%; under continued antibiotic treatment for a
mean of 6 months. Following hospital discharge, freedom from
reoperation was also 100%. Some additional cases were recently
published in the Multimedia Manual of Cardiothoracic Surgery
to add some practical issues when dealing with such a pathology
[3]. The most interesting points of self-constructed xenopericar-
dial vascular grafts are (i) that the material is always available (in
contrary to homografts), and (ii) that the size and the length of
the aortic segment and/or supraaortic branches to be recon-
structed can be chosen accordingly, from 8 mm to approximate-
ly 25 mm. The picture shows a case where not only the
ascending aorta and the arch had to be replaced, but also the
innominate artery and the left common carotid artery [4] (Fig. 1).
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Figure 1: Reconstruction of the ascending aorta, the aortic arch as well as the
innominate artery and the left common carotid artery in a severe recurrent
aortic infection, using xenopericardial tube grafts. (Synovis Surgical
Innovations, St. Paul, MN, USA; Supple PeriGuard 8 cm × 14 cm). Both illustra-
tions copyright by Elsevier [2, 4].
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